Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer

Li, Xiaoyuan; Zhou, Jianfeng; Chen, Shuchang; Guan, Mei; Wang, Yingyi; Zhao, Lin; Ying, Hongyan; Zhou, Yanping

doi:10.1177/0300060514527058

Cited by 20 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Empirically, for the treatment of mild to moderate drug-induced hepatocellular injury or mixed liver injury, bicyclol [133, 134], and glycyrrhizic acid [135] may be considered to treat patients with severe liver inflammation, and silymarin [136] may be selected to treat those with mild liver inflammation. It is reported that both ursodeoxycholic acid (UDCA) [137, 138] and S -adenosyl methionine (SAMe) [139–141] have therapeutic effects in patients with cholestatic DILI.…”

Section: Treatment Of Dilimentioning

confidence: 99%

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

et al. 2017

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.

show abstract

Section: Treatment Of Dilimentioning

confidence: 99%

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In the People’s Republic of China, BY is clinically prescribed for the treatment of liver injury/viral hepatitis. 22 , 23 …”

Section: Introductionmentioning

confidence: 99%

Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

Zhu¹,

Pan²,

Zhou³

et al. 2015

DDDT

View full text Add to dashboard Cite

BackgroundCurrently, combined therapy using herbs and synthetic drugs has become a feasible therapeutic intervention against some diseases. The purpose of this study was to assess the effects of supplementation with fenofibrate (FF), a chemical drug used for the treatment of hyperlipidemia, and the aqueous extract of Schisandrae Fructus (SF, a Chinese herb) pulp (AqSF-P) or an SF-related synthetic analog, bicyclol (BY), on serum/hepatic lipid levels and liver status in normal and hypercholesterolemic (HCL) mice.MethodsMale mice obtained from the Institute of Cancer Research (ICR) were fed on a normal diet (ND) or high cholesterol/bile salt (0.5%/0.15%, w/w) diet (HCBD) containing FF (0.03% or 0.1%, w/w) with or without AqSF-P (0.3%−9.0%, based on crude herbal material, w/w) or BY (0.025%, w/w) for 10 days. Then serum lipid levels and alanine aminotransferase (ALT) activity, as well as hepatic triglyceride (TG), total cholesterol (TC), and glucose levels, were measured.ResultsOral supplementation with FF significantly reduced serum and hepatic TG, TC, and hepatic glucose levels (approximately 79%) in mice fed with ND or HCBD. FF supplementation combined with AqSF-P or BY increased FF-induced reduction in hepatic TC and TG contents in ND-fed mice (up to 67%) and in HCBD-fed mice (up to 54%), when compared with FF supplementation alone. Hepatic glucose-lowering effect of FF was enhanced (up to 19%) by AqSF-P cosupplementation in both normal and HCL mice. FF supplementation enhanced the excretion of fecal TC (by 75%) in mice fed with HCBD. Fecal TC contents were increased by 14%/9% in the combination therapy with FF and AqSF-P in ND-/HCBD-fed mice. Serum ALT activity was elevated by 45% in HCBD-fed mice. FF caused a significant increase in ALT activity by 198% and 120% in normal and HCL mice, respectively. BY markedly attenuated the ALT activity by 54% in mice fed with ND supplemented with 0.1% FF and by 42% in mice fed with HCBD supplemented with 0.03% FF.ConclusionAqSF-P cosupplementation augmented the hepatic lipid-/glucose-lowering effects of FF. BY ameliorated FF-induced liver injury in normal and HCL mice.

show abstract

“…Chu and collegues [20] proved that Bicyclol tablets for liver-protective treatment combined with other basic liver-protective treatments can prevent the occurrence of liver injuries induced by antituberculosis drugs in patients with basic liver diseases, and guarantee successful antituberculosis treatment. Li et al [21] showed that Bicyclol tablets for liver-protective treatment combined with chemotherapy can reduce the occurrence and severity of DILIs in elderly cancer patients above 60 years, and guarantee the safety and tolerance of chemotherapy. Li Bing et al [22] showed that therapeutic dosage (25 mg, 3 times/d) of Bicyclol tablets does not affect the Tac blood concentration of patients who have accepted kidney transplantation.…”

Section: Discussionmentioning

confidence: 99%

Effect of Bicyclol tablets on drug induced liver injuries after kidney transplantation

et al. 2017

View full text Add to dashboard Cite

AbstractLiver injury is one of the most common complications in patients after kidney transplantation. Bicyclol tablets possess obvious anti-inflammatory and liver-protective functions. This study aimed to explore the clinical effect of preventive application of Bicyclol on drug induced liver injuries at an early stage after kidney transplantation.A total of 1600 patients who accepted kidney transplantations at our hospital from January 2009 to May 2015 were enrolled in this study, and divided into the prevention group (Bicyclol) and the control group (no hepatic protectors) based on whether or not hepatic protectors were regularly administered after the operation. The occurrence of liver injuries at an early stage after the operation and their influencing factors were analyzed.Total of 745 cases were included in the final analysis of which 82 developed liver injuries post-operation, with 22 in the prevention group (4.82%) as compared to 60 in the control group (20.76%) (P= 0.001). As compared to the control group, OR (95% CI) of the prevention group was 0.197 (0.116, 0.334) after revising HBsAg status, age and maintenance immunosuppression.Prophylactic application of Bicyclol as liver-protective treatment was a protective factor against drug induced liver injuries at an early stage after kidney transplantation.

show abstract

Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer

Cited by 20 publications

References 15 publications

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

Effect of Bicyclol tablets on drug induced liver injuries after kidney transplantation

Contact Info

Product

Resources

About